Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola Sells 9,059 Shares

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola sold 9,059 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $5.80, for a total transaction of $52,542.20. Following the sale, the chief financial officer now directly owns 74,752 shares of the company’s stock, valued at approximately $433,561.60. The trade was a 10.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Terns Pharmaceuticals Trading Down 0.7 %

Shares of TERN opened at $5.71 on Tuesday. Terns Pharmaceuticals, Inc. has a 12-month low of $4.32 and a 12-month high of $11.40. The company has a market capitalization of $485.00 million, a PE ratio of -4.84 and a beta of -0.31. The business’s 50 day moving average is $6.35 and its 200 day moving average is $7.41.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. Equities research analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC purchased a new stake in shares of Terns Pharmaceuticals in the third quarter worth about $48,000. Sio Capital Management LLC purchased a new stake in shares of Terns Pharmaceuticals during the 3rd quarter worth approximately $83,000. Entropy Technologies LP purchased a new stake in shares of Terns Pharmaceuticals during the 3rd quarter worth approximately $106,000. Bleakley Financial Group LLC boosted its position in shares of Terns Pharmaceuticals by 26.0% during the 3rd quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company’s stock valued at $111,000 after acquiring an additional 2,751 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Terns Pharmaceuticals by 78.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,535 shares of the company’s stock valued at $113,000 after purchasing an additional 5,935 shares in the last quarter. Institutional investors own 98.26% of the company’s stock.

Analyst Upgrades and Downgrades

TERN has been the subject of several recent research reports. HC Wainwright reissued a “neutral” rating and set a $7.50 price target on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. BMO Capital Markets reiterated an “outperform” rating and set a $26.00 price objective (up from $19.00) on shares of Terns Pharmaceuticals in a research note on Monday, September 16th. Oppenheimer raised their target price on shares of Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 4th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $20.00 price target on shares of Terns Pharmaceuticals in a research report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.30.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.